Market Size of Europe Biobanks Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Historical Data Period | 2019 - 2022 |
CAGR | 6.50 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Europe Biobanks Market Analysis
Stem cell practices are on the rise in European countries and are contributing to the development of new solutions for various diseases. Several advancements have been made in regenerative medicine through stem cell technology over the past decade. Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases. To benefit from the existing therapies, umbilical cord cells and other stem cells are preserved in Biobanks. The European Science Foundation (ESF) has been an active player in advancements made in stem cell and regenerative medicine research and in providing new treatments for incurable diseases and opportunities. With the increase in awareness about stem cell therapies, there have been a larger number of parents, who choose umbilical cord banks for their children. Biobanks not only aid in the therapies for genetic diseases, but also in medical research on rare genetic disorders. However, other factors such as rising burden of chronic diseases and R&D funding and investments by government and non-governmental organizations are also expected to drive the market in the forecast period.
Europe Biobanks Industry Segmentation
As per the scope of the report, Biobanks are the bio-repository, wherein various biomaterials (usually human specimens) are stored for research purposes. This study targets gaining a detailed overview of the market dynamics of the contemporary biobank market during the forecast period.
Equipment | |||||
| |||||
Alarm Monitoring Systems | |||||
Other Equipment |
Media | |
Optimized Media | |
Non-optimized Media |
Services | |
Human Tissue Biobanking | |
Stem Cell Biobanking | |
Cord Banking | |
DNA/RNA Biobanking | |
Other Services |
By Application | |
Regenerative Medicine | |
Drug Discovery | |
Disease Research |
Europe Biobanks Market Size Summary
The European biobanks market is experiencing significant growth, driven by the increasing adoption of stem cell practices and advancements in regenerative medicine. This sector plays a crucial role in developing new treatments for various diseases, including Alzheimer's, diabetes, cancer, and rare genetic disorders. Biobanks are essential for preserving umbilical cord cells and other stem cells, which are vital for these therapies. The European Science Foundation has been instrumental in promoting research and providing new treatment opportunities, further boosting market expansion. The growing awareness and preference for stem cell therapies among parents opting for umbilical cord banking are also contributing to market growth. Additionally, the rising prevalence of chronic diseases and increased funding for research and development by both governmental and non-governmental organizations are expected to drive the market forward.
The market is characterized by a competitive landscape, with key players such as Atlanta Biologicals Inc., Becton, Dickinson and Company, BioLifeSolutions Inc., Hamilton Company, Qiagen N.V., Stemcell Technologies Inc., and Thermo Fisher Scientific leading the charge. These companies are instrumental in providing essential equipment and technologies, including cryogenic storage systems and alarm monitoring systems, which are crucial for the effective operation of biobanks. The demand for automated storage systems and advanced monitoring devices is on the rise, fueled by technological advancements and the need for continuous process monitoring. This competitive environment, coupled with the entry of new players, is expected to further stimulate market growth in the coming years.
Europe Biobanks Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Advancements in Stem Cell and Regenerative Medicine Research
-
1.2.2 Rising Burden of Chronic Diseases
-
1.2.3 R&D Funding and Investments by Government and Non-Governmental Organizations
-
-
1.3 Market Restraints
-
1.3.1 Regulatory Issues
-
1.3.2 Cost Constraints
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Equipment
-
2.1.1 Cryogenic Storage Systems
-
2.1.1.1 Refrigerators
-
2.1.1.2 Ice Machines
-
2.1.1.3 Freezers
-
-
2.1.2 Alarm Monitoring Systems
-
2.1.3 Other Equipment
-
-
2.2 Media
-
2.2.1 Optimized Media
-
2.2.2 Non-optimized Media
-
-
2.3 Services
-
2.3.1 Human Tissue Biobanking
-
2.3.2 Stem Cell Biobanking
-
2.3.3 Cord Banking
-
2.3.4 DNA/RNA Biobanking
-
2.3.5 Other Services
-
-
2.4 By Application
-
2.4.1 Regenerative Medicine
-
2.4.2 Drug Discovery
-
2.4.3 Disease Research
-
-
Europe Biobanks Market Size FAQs
What is the current Europe Biobanks Market size?
The Europe Biobanks Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in Europe Biobanks Market?
BioLifeSolutions Inc., Hamilton Company, Sigma-Aldrich Inc. (Merck KGaA), Thermo Fisher Scientific Inc. and VWR International LLC are the major companies operating in the Europe Biobanks Market.